Bhupendar Tayal
Sourced from institutional research profiles (UAMS TRI or ARA).
Assistant Professor
COM | Internal Med Cardiology
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Bhupendar Tayal, Assistant Professor in Internal Medicine Cardiology at the University of Arkansas for Medical Sciences, studies cardiovascular conditions and their treatment. His research has focused on cardiac resynchronization therapy (CRT), investigating methods to predict patient response and long-term outcomes. This includes utilizing echocardiography and electrocardiography to identify specific patient substrates that benefit from CRT, such as typical left bundle branch block contraction and systolic stretch. Tayal has also examined the incidence of heart failure following pacemaker implantation and characterized right ventricular remodeling in pulmonary hypertension using advanced echocardiographic techniques. His work further explores the relationship between myocardial scar and mortality in chronic aortic regurgitation. Tayal's scholarship metrics include an h-index of 18, with 128 total publications and 1,266 total citations.
Metrics
- h-index: 18
- Publications: 128
- Citations: 1,266
Positions
-
Assistant Prof. 2025–presentUniversity of Arkansas for Medical Sciences Cardiology ORCID
-
Assistant ProfessorUniversity of Arkansas for Medical Sciences COM | Internal Med Cardiology Institutional directory
-
Assistant Prof. 2022–2025Case Western Reserve University Cardiology ORCID
Selected Publications
-
AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)
-
Prognostic importance of septal deformation patterns and lateral wall function in patients with heart failure and left bundle branch block receiving cardiac resynchronization therapy (2026)
-
Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram (2026)
-
26-A-21124-ACC PREDICTORS OF MYOCARDIAL RECOVERY IN HEART FAILURE WITH REDUCED EJECTION FRACTION (2026)
-
26-A-18480-ACC INCIDENCE AND PREDICTORS OF HIGH-GRADE ATRIOVENTRICULAR BLOCK AFTER TRANSCATHETER TRICUSPID VALVE REPLACEMENT: A REAL-WORLD ANALYSIS (2026)
-
26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS (2026)
-
26-A-16106-ACC SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) IN PULMONARY HYPERTENSION (PH): A SYSTEMATIC REVIEW (2026)
-
26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS (2026)
-
1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia (2026)
-
Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study (2025)
-
Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve (2025)
Collaboration Network
Top Collaborators
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-21124-ACC PREDICTORS OF MYOCARDIAL RECOVERY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- 26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
- 26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS
- 26-A-16106-ACC SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) IN PULMONARY HYPERTENSION (PH): A SYSTEMATIC REVIEW
- 26-A-18480-ACC INCIDENCE AND PREDICTORS OF HIGH-GRADE ATRIOVENTRICULAR BLOCK AFTER TRANSCATHETER TRICUSPID VALVE REPLACEMENT: A REAL-WORLD ANALYSIS
- 26-A-16106-ACC SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) IN PULMONARY HYPERTENSION (PH): A SYSTEMATIC REVIEW
- 26-A-18480-ACC INCIDENCE AND PREDICTORS OF HIGH-GRADE ATRIOVENTRICULAR BLOCK AFTER TRANSCATHETER TRICUSPID VALVE REPLACEMENT: A REAL-WORLD ANALYSIS
- 26-A-21124-ACC PREDICTORS OF MYOCARDIAL RECOVERY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
Similar Researchers
Based on overlapping research topics